Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06856577 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, sponsored by Adverum Biotechnologies.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
- 20
- Study locations
NCT06856577 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD that is actively recruiting participants, run by Adverum Biotechnologies. The registered enrollment target is 284 participants, above the 177-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06856577, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, is actively recruiting participants, sponsored by Adverum Biotechnologies.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.
Conditions Studied
Interventions
- GENETIC Ixo-vec
- DRUG Aflibercept
Study Locations (20)
California
- Adverum Clinical Site 109 - Bakersfield
- Adverum Clinical Site 100 - Beverly Hills
- Adverum Clinical Site 201 - Campbell
- Adverum Clinical Site 172 - Encino
- Adverum Clinical Site 169 - Fullerton
- Adverum Clinical Site 224 - Huntington Beach
- Adverum Clinical Site 215 - Redlands
- Adverum Clinical Site 164 - Riverside
- Adverum Clinical Site 140 - Sacramento
- Adverum Clinical Site 212 - Sacramento
- Adverum Clinical Site 175 - Santa Barbara
- Adverum Clinical Site 202 - Torrance
- Adverum Clinical Site 189 - Walnut Creek
Arizona
- Adverum Clinical Site 223 - Gilbert
- Adverum Clinical Site 178 - Phoenix
- Adverum Clinical Site 126 - Phoenix
- Adverum Clinical Site 229 - Scottsdale
- Adverum Clinical Site 159 - Tucson
Arkansas
- Adverum Clinical Site 198 - Springdale
Colorado
- Adverum Clinical Site 200 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2030-11-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06856577
The ClinicalTrials.gov registry entry for NCT06856577 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (60% higher). The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which Ixo-vec is the first listed.
NCT06856577 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06856577 about?
NCT06856577 is a clinical study titled "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration". This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection o...
What is the current status of trial NCT06856577?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2025-02-28. Estimated completion is 2030-11-23.
What conditions does trial NCT06856577 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD), Wet AMD.
What interventions are being tested in trial NCT06856577?
The interventions under investigation include: Ixo-vec (GENETIC), Aflibercept (DRUG).
Who is sponsoring clinical trial NCT06856577?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06856577 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
RECRUITING · Phase 3
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
COMPLETED · Phase 3
-
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
COMPLETED · Phase 3
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.